In clinical trials the most common adverse events leading to discontinuation were [[nausea]], [[diarrhea]], and vomiting.<ref>{{cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020690s037,021720s010,022568s007lbl.pdf |title=www.accessdata.fda.gov |format= |work= |accessdate=}}</ref><ref>{{cite journal |vauthors=Noetzli M, Eap CB | date = Apr 2013 | title = Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease | url = | journal = Clin Pharmacokinet | volume = 52 | issue = 4| pages = 225â€“41 | doi = 10.1007/s40262-013-0038-9 | pmid = 23408070 }}</ref> Other side effects included difficulty sleeping, muscle cramps and anorexia. Most side effects were observed in patients taking the 23&nbsp;mg dose compared to 10&nbsp;mg or lower doses. Side effects improved with continued use.<ref name="ReferenceA" />

 

